Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03590054 · ClinicalTrials.gov registry record · Phase 1
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study of Metastatic Malignant Solid Neoplasm and Metastatic Melanoma, sponsored by Rahul Aggarwal.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03590054 is a Phase 1 study of Metastatic Malignant Solid Neoplasm and Metastatic Melanoma that has completed, run by Rahul Aggarwal. The registered enrollment target is 35 participants, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03590054, a Phase 1 study of Metastatic Malignant Solid Neoplasm and Metastatic Melanoma, has completed, sponsored by Rahul Aggarwal.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Abexinostat
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03590054
The ClinicalTrials.gov registry entry for NCT03590054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (83% lower). The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03590054 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03590054 about?
NCT03590054 is a clinical study titled "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies". This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cel...
What is the current status of trial NCT03590054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-08-20. Estimated completion is 2023-11-30.
What conditions does trial NCT03590054 study?
This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Small-Cell Lung Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma.
What interventions are being tested in trial NCT03590054?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Abexinostat (DRUG).
Who is sponsoring clinical trial NCT03590054?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03590054 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RECRUITING · Phase 1
-
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
RECRUITING · Phase 1
-
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RECRUITING · Phase 1
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.